How medical device manufacturers can ace cybersecurity assessment

Medical device manufacturers are facing a threat environment that has fundamentally changed. 24% of healthcare organizations were hit by medical device cyberattacks in 2026, and those attacks directly impacted patient care. That number should alarm every product team still treating cybersecurity as a final checklist item. Regulators have noticed, and the FDA has responded with guidance that makes robust security assessment a hard requirement for market entry. This guide walks you through exactly what assessors look for, what evidence you need to produce, and how to build a program that passes the first time.

Table of Contents

• Why cybersecurity assessments matter for medical devices
• FDA guidance and mandatory evidence: What you need to show
• Building an audit-ready cybersecurity program
• Addressing emerging threats and complex environments
• The uncomfortable truth: Why most manufacturers struggle—and what works
• How Testvox can help streamline your cybersecurity assessment
• Frequently asked questions

Key Takeaways

Why cybersecurity assessments matter for medical devices

The stakes here are not abstract. When a connected infusion pump gets compromised or a cardiac monitor is taken offline by ransomware, patients get hurt. Cyberattacks on medical devices are no longer rare edge cases; they are a documented, growing pattern with real clinical consequences.

“The data is clear: attacks on medical devices are rising, procurement standards are tightening, and manufacturers who treat cybersecurity as optional are being left behind by both regulators and hospital buyers.”

The numbers reinforce this urgency. 80% of medical device attacks directly impact patient care, with the primary causes being unpatched vulnerabilities and outdated operating systems. These are not sophisticated zero-day exploits. They are known, documented weaknesses that manufacturers simply failed to address.

The FDA responded by finalizing comprehensive FDA cybersecurity requirements in June 2025. This guidance requires threat modeling, assessment, and documentation for all cyber devices as part of the quality management system and premarket submission process. Compliance is no longer optional or aspirational.

The risk landscape includes several distinct threat categories:

• Legacy systems: Devices running end-of-life operating systems with no patch pathway
• IoT and connected devices: Expanded attack surface from network-connected sensors and monitors
• AI integration: New algorithmic components that introduce data integrity and model manipulation risks
• Third-party software components: Supply chain vulnerabilities embedded in commercial off-the-shelf software
• Remote access features: Telehealth and remote diagnostics capabilities that open external entry points

Understanding these categories helps you scope your assessment correctly from the start. Trying to address them after design lock is where most manufacturers lose time and money. Reviewing the full landscape of compliance steps early in your product lifecycle will save you significant rework later.

FDA guidance and mandatory evidence: What you need to show

The FDA’s 2025 guidance is specific about what manufacturers must submit. Vague security statements and generic risk matrices will not satisfy reviewers. You need structured, traceable evidence that maps directly to your device’s threat landscape.

Here is a side-by-side comparison of traditional safety assessment versus modern cybersecurity assessment to clarify the shift:

The FDA’s 2025 guidance specifies required evidence including threat modeling, a software bill of materials (SBOM), and a cybersecurity risk assessment tied directly to exploitability. Here are the core required elements for your submission:

1. Cybersecurity management plan: A living document that describes how you will identify, assess, and respond to vulnerabilities throughout the device lifecycle.
2. Threat model: A structured analysis of potential adversaries, attack vectors, and the impact of successful exploitation on patient safety and device function.
3. Software bill of materials (SBOM): A complete inventory of every software component, library, and dependency in your device, including version numbers and known vulnerabilities.
4. Exploitability-based risk assessment: Risk scoring that accounts for how easily an attacker can actually exploit a given vulnerability, not just the theoretical severity.
5. Penetration testing results: Structured testing conducted against the actual device, documented according to a recognized framework. The UL 2900-2-1 standard provides a solid framework for structured pen testing and documenting compliance.
6. Post-mitigation scoring: Updated risk scores showing how your controls reduce exploitability, not just theoretical severity.

One critical point that catches many manufacturers off guard: FDA may reject substantial equivalence if cybersecurity risks are inadequately addressed. This means a weak cybersecurity submission can block your entire 510(k) clearance, regardless of how strong your clinical or safety data is. Review our penetration testing guide for a detailed breakdown of what structured testing looks like in practice.

Understanding exploitability-based risk is worth a moment of extra attention. Traditional risk assessment asks: “How bad would it be if this failed?” Exploitability-based assessment asks: “How easy is it for an attacker to make this fail?” A vulnerability with moderate severity but trivial exploitability is actually a high-priority risk. Many teams using legacy ISO 14971 frameworks miss this distinction entirely, which is why their submissions get flagged. Our risk assessment frameworks page covers the specific methodologies that align with FDA expectations.

Pro Tip: Start building your cybersecurity documentation during the design phase, not after design freeze. Retrofitting threat models and SBOMs onto a finished design is painful, expensive, and usually obvious to experienced auditors. Documentation that grows with your design is far more credible.

Building an audit-ready cybersecurity program

Knowing what documents you need is only part of the challenge. The harder part is building the organizational processes that produce those documents reliably and keep them current. Here is a practical sequence for getting audit-ready:

1. Designate a Chief Product Security Officer (CPSO) or equivalent: Someone needs to own cybersecurity accountability. Organizations that assign CPSO ownership and use maturity frameworks consistently outperform peers in assessment outcomes. Without clear ownership, security tasks fall through the cracks.
2. Select and implement a maturity framework: Frameworks like NIST CSF or the MDIC Cybersecurity Playbook give you a structured way to measure your current state and plan improvements. They also give auditors a familiar reference point.
3. Build your SBOM from day one: Every third-party library, open-source component, and commercial software element needs to be cataloged with version numbers. Tools like SPDX or CycloneDX make this manageable.
4. Conduct threat modeling during design: Use structured methodologies like STRIDE or PASTA to identify attack vectors before they get baked into your architecture. The FDA’s guidance explicitly calls for threat modeling as a core methodology alongside pre/post-mitigation scoring.
5. Schedule and execute penetration testing: Real-world testing against your actual device is non-negotiable. Paper-based assessments alone will not satisfy reviewers. Plan for both pre-release and periodic post-market testing.
6. Establish a vulnerability disclosure and patch management process: Your cybersecurity management plan must describe how you will respond when new vulnerabilities are discovered, including timelines and communication protocols.
7. Review and update before submission: Do a complete audit of all documentation for consistency, traceability, and completeness before filing. Gaps between your threat model and your testing scope are a common rejection trigger.

The following table summarizes common device vulnerabilities and the recommended patch strategies:

Pro Tip: Use threat modeling tools like Microsoft Threat Modeling Tool or IriusRisk early in your design process. Pairing these with a recognized maturity framework helps you catch architectural risks before they become expensive redesigns. Explore our penetration testing startup guide for practical guidance on scoping and executing your first formal test. Also review how to avoid compliance mistakes that commonly trip up teams during final submission reviews.

Addressing emerging threats and complex environments

The threat landscape is not static. Three technology shifts are actively expanding the attack surface for medical devices: AI integration, cloud connectivity, and widespread remote access. Each one changes the scope of what your cybersecurity assessment needs to cover.

The MDIC 2025 Cybersecurity Benchmark confirms that AI, cloud use, and post-quantum cryptography risks are shifting security exposure toward third parties and home-use environments, complicating traditional assessment models. A device that was previously assessed as a standalone unit may now have a cloud-connected companion app, a remote monitoring portal, and an AI-driven diagnostic algorithm. Each of those components needs to be included in your threat model and tested accordingly.

Legacy devices present a separate and particularly stubborn challenge. 99% of hospitals have IoMT devices with known exploited vulnerabilities in their networks, and a staggering 60% of medical devices are end-of-life and unpatchable. That means more than half the connected devices in clinical environments cannot be fixed through traditional software updates. If your device operates in that environment, your assessment needs to account for the risks posed by neighboring devices, not just your own.

Practical mitigation tactics for these complex environments include:

• Keep SBOMs continuously updated: Static SBOMs become outdated quickly. Automate alerts when new CVEs affect components in your bill of materials.
• Require third-party attestations: Any software or service provider that connects to your device should provide documented security attestations. Do not assume their security posture is adequate.
• Implement network segmentation controls: Design your device to operate safely even when surrounded by compromised network neighbors.
• Monitor for orphaned vulnerabilities: Components that are no longer actively maintained but still present in your device create silent exposure. Regular SBOM audits catch these before regulators do.
• Plan for post-quantum cryptography migration: If your device has a long service life, the encryption algorithms you use today may be breakable before the device reaches end of life. Start planning your migration pathway now.
• Document AI model integrity controls: If your device uses machine learning, document how you protect model inputs and outputs from adversarial manipulation.

For a deeper look at how to fix healthcare device gaps in complex environments, explore the specific control frameworks that apply to IoT and AI-enabled devices.

The uncomfortable truth: Why most manufacturers struggle—and what works

Here is what we see repeatedly when manufacturers come to us after a failed submission or a difficult audit: they treated cybersecurity as a documentation exercise rather than a security exercise. They gathered the required paperwork, checked the required boxes, and submitted. Then they were surprised when reviewers pushed back.

The core problem is that most teams still think about cybersecurity assessment the way they think about a traditional design review. You gather evidence, you present it, you pass. But cybersecurity reviewers are not just checking whether documents exist. They are evaluating whether your security posture is credible. A threat model that does not align with your actual architecture, or a penetration test that only covers obvious attack vectors, signals that your team does not genuinely understand the risk.

“Maturity leaders integrate security early, leverage the total product lifecycle, and assign clear ownership. That combination consistently outperforms teams that rely on late-stage documentation sprints.” — MDIC 2025 Cybersecurity Benchmark

Documentation retrofits are particularly damaging. When a team builds a device and then writes the threat model afterward, the threat model reflects what they built, not what they should have built. Auditors with experience can spot this pattern. The threat model will be suspiciously clean, the risks will all be neatly mitigated, and the testing scope will conveniently match the documented architecture. Real threat models are messier because real design processes are messy.

What actually works, based on what security risk assessment insights from high-performing organizations consistently show:

• Assign a CPSO early: Not just a title, but genuine authority and accountability for security decisions throughout the product lifecycle.
• Use a maturity framework as a management tool: Not just for auditors, but as an internal compass for where your program is strong and where it needs investment.
• Continually update your SBOM: Treat it as a living operational document, not a submission artifact.
• Run real-world testing, not paper exercises: Actual penetration testing against actual hardware and software, conducted by testers who are trying to break things.
• Integrate security into your design review process: Every design decision should include a security impact assessment, not just a safety impact assessment.

The manufacturers who consistently pass assessments on the first attempt are not the ones with the most sophisticated security programs. They are the ones who started early, assigned ownership, and built security into their process rather than onto their product.

How Testvox can help streamline your cybersecurity assessment

If your team is preparing for an FDA cybersecurity submission or wants to close gaps before a formal audit, the path forward is clearer than it might seem.

Testvox provides security testing services specifically designed for medical device manufacturers navigating FDA compliance requirements. Our VAPT specialists understand the documentation standards, exploitability-based risk frameworks, and penetration testing protocols that regulators expect. We have worked with device manufacturers to produce audit-ready evidence packages, including threat models, SBOM reviews, and structured pen testing aligned with UL 2900-2-1. Our FDA-ready device security testing case study shows exactly how we helped a patient monitoring device team achieve compliance without last-minute surprises. Reach out to Testvox to build a testing program that accelerates your path to market.

Frequently asked questions

What documents must manufacturers provide for FDA cybersecurity assessment?

Manufacturers must provide a cybersecurity management plan, threat modeling evidence, risk assessments based on exploitability, a software bill of materials (SBOM), and security testing results. FDA’s 2025 guidance requires all of these elements for cyber device premarket submissions.

What is exploitability-based risk assessment?

Exploitability-based risk assessment prioritizes security risks based on how easily an adversary can exploit a vulnerability, not just the theoretical harm it could cause. FDA’s evidence requirements specifically call for pre/post-mitigation scoring grounded in exploitability.

How often should cybersecurity policies be updated for medical devices?

Policies should be revisited at minimum annually, and immediately whenever a technology change, new platform integration, or significant new vulnerability affects your device’s risk profile.

Why are so many medical devices vulnerable to cyberattacks?

Many devices run outdated operating systems, and 60% are end-of-life unpatchable, meaning traditional software updates cannot close known security gaps, leaving them permanently exposed to documented exploits.

What’s the benefit of using a cybersecurity maturity framework?

Organizations using maturity frameworks and assigning clear ownership consistently deliver stronger compliance outcomes. Maturity leaders outperform peers in both audit performance and real-world security posture because they treat security as a program, not a project.

Recommended

• Medical device security risk assessment for stronger compliance
• Medical device cybersecurity: compliance steps to enter the market
• How to spot and fix cybersecurity gaps in healthcare devices
• Meet Notified Body cybersecurity requirements confidently